FIELD: biotechnology.
SUBSTANCE: antibody binding HER2 is proposed, including injected Cys residues for site-specific conjugation. Antibody-drug conjugate (hereinafter – ADC) containing the specified antibody conjugated with a therapeutic agent and a pharmaceutical composition for the treatment of cancer including ADC are also proposed.
EFFECT: invention provides for obtaining ADC with improved pharmacokinetic profile.
11 cl, 42 dwg, 50 tbl, 25 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SITE-SPECIFIC HER2 ANTIBODY-DRUG CONJUGATES | 2016 |
|
RU2745565C2 |
| ANTIBODIES AGAINST EDB AND ANTIBODY-DRUG CONJUGATES | 2017 |
|
RU2758632C2 |
| AIMED AT UPARAP ANTIBODY-DRUG CONJUGATES | 2017 |
|
RU2740311C2 |
| AMATOXIN ANTIBODY-DRUG CONJUGATES AND USE THEREOF | 2020 |
|
RU2826004C2 |
| HUMAN ANTIBODIES BINDING TO ROR2 | 2018 |
|
RU2784586C2 |
| METHODS FOR PREPARING ANTIBODY-DRUG CONJUGATE COMPOSITIONS | 2015 |
|
RU2741470C2 |
| ANTIBODIES AND ANTIBODY-DRUG CONJUGATES SPECIFIC TO CD123 AND THEIR USE | 2018 |
|
RU2789150C2 |
| CONJUGATE OF ANTI-CEA ANTIBODY AND EXCATECAN ANALOGUE AND PHARMACEUTICAL USE THEREOF | 2020 |
|
RU2833323C1 |
| ANTIBODIES AGAINST CD79b, DRUG CONJUGATES AND THEIR USE | 2019 |
|
RU2805251C2 |
| CONJUGATE OF ANTI-CLAUDIN ANTIBODY AND MEDICINAL AGENT AND PHARMACEUTICAL USE THEREOF | 2020 |
|
RU2826119C1 |
